Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next? Five Things To Look Out For In December

Two Biosimilar Products Face FDA Action Dates

Executive Summary

Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.

You may also be interested in...



AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar

With the US biosimilar Avastin market now more than a year old, another potential player, Centus Biotherapeutics, finds itself facing trial over its biosimilar candidate. The UK-based joint venture already boasts approval from the European Commission for its FKB238 product, Equidacent.

Truxima Hits 20% Share For Teva

Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.

Sun Sees US Sales Pick Up

Sun enjoyed a sequential improvement in its US sales in Q2, with finished-dosage turnover in the market up by almost a fifth over the financial first quarter. Meanwhile, the Indian company is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola. 

Related Content

Topics

UsernamePublicRestriction

Register

GB150482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel